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Edited by Varda RotterAbstract It has been assumed that prostaglandin (PG)I2 signal-
ing contributes to the negative growth control of lung cancer
cells; however, the mechanism remains unresolved. PGI2 func-
tions through a cell surface G protein-coupled receptor (prosta-
glandin I2-binding receptor, IP) and also exerts an eﬀect by
interacting with a nuclear hormone receptor, peroxisome prolif-
erator-activated receptor d (PPARd). We found that PPARd
was a key molecule of PGI2 signaling to give negative growth
control of lung cancer cells (A549), using carbarprostacyclin, a
PGI2 agonist for IP and PPARd, and L-165041, a PPARd ago-
nist. Furthermore, PPARd-induced cell growth control was rein-
forced by the inhibition of cyclooxygenase. These results suggest
that PPARd activation under the suppression of PG synthesis is
important to regulate lung cancer cell growth.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: PPAR-d; IP; PGI2; Lung cancer cell; Growth
control1. Introduction
Lung cancer, particularly non-small cell lung cancer
(NSCLC), is one of the most common cancers and is the lead-
ing cause of cancer death in Western countries as well as Japan
[1,2]; of NSCLC, the adenocarcinoma type has the most dom-
inant histology [3]. Recently, it has been suggested that cyclo-
oxygenase-2 (COX-2) is a useful diagnostic marker and target
for the prevention and therapy of lung adenocarcinoma [4,5].
The induction of COX-2 is associated with high levels of pros-
taglandin E2 (PGE2) production in lung adenocarcinoma cells
and these high levels stimulate cell growth [6]. However, hu-
man trials evaluating COX inhibitor and lung cancer chemo-
prevention remain to be completed, and furthermore, COX-2
inhibition by celecoxib leads to no change in tumor multiplic-Abbreviations: PPARd, peroxisome proliferator-activated receptor d;
PG, prostaglandin; IP, prostaglandin I2-binding receptor; COX, cyc-
looxygenase; SSAT, spermidine/spermine N1-acetyltransferase
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model of lung tumorigenesis [7]. These reports suggest that fac-
tors other than COX-2 expression are required for the develop-
ment of lung adenocarcinoma. Thus, determination of these
other factors may lead to the establishment of a new preven-
tion and therapy regime against lung cancer.
PGH2 produced by COX-2 is converted into one of several
biologically important prostaglandins (PGs), including PGE2
and PGI2, by each speciﬁc synthase [8,9], and PGs have
wide-ranging eﬀects in regulating aspects of homeostasis and
pathogenesis [10]. Diﬀerent from other PGs, PGI2 acts as an
inhibitory factor against the development of cancers; for exam-
ple, PGI2 reduces the growth of established micrometastases
[11]. In normal lungs, PGI2 is one of the most abundant
PGs, but the production of PGI2 by lung adenocarcinoma cells
is suppressed to a very low level [12]. In contrast, a high level of
PGE2 linked with the induction of COX-2 is observed in lung
adenocarcinoma cells [6]. From these reports, it is speculated
that, in addition to the induction of COX-2, the suppression
of PGI2 production contributes to the development of lung
adenocarcinoma. The downregulation of PGI2 synthase is ob-
served in lung adenocarcinoma tissue, and the expression of
PGI2 synthase in lungs leads to the reduced development of
lung adenocarcinoma in mice [13,14]. However, it remains un-
clear which signaling pathway regulated by PGI2 contributes
to the reduction of lung cancer.
Since PGI2 functions through a G protein-coupled cell sur-
face receptor, termed IP (prostaglandin I2-binding receptor),
and also exerts an eﬀect by interacting with a nuclear hormone
receptor, peroxisome proliferator-activated receptor d
(PPARd) [15,16], we examined which of these two receptors
could play an important role in the PGI2-regulated signaling
of lung adenocarcinoama cells (A549). Furthermore, we at-
tempted to clarify why the level of PGI2 was much lower than
that of other PGs in lung adenocarcinoma cells. Finally, as a
result of these investigations, we propose that PPARd is a
promising target to regulate lung cancer cell growth.2. Materials and methods
2.1. Chemicals
All chemicals were purchased from Sigma (St. Louis, MI, USA) un-
less otherwise stated. Carbaprostacyclin (cPGI2) was from Cayman
Chemical Co. (Ann Arbor, MI, USA).blished by Elsevier B.V. All rights reserved.
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A human lung adenocarinoma cell line, A549 cell was provided by
Riken Cell Bank (Saitama, Japan). This cell was routinely maintained
in Dulbeccos modiﬁed eagles medium (DMEM) (Gibco-BRL, Tokyo,
Japan) supplemented with 10% fetal bovine serum (FBS) and penicil-
lin–streptomycin. For experiments, exponentially growing cells were
used in DMEM medium containing 2% FBS (culture medium) unless
otherwise stated. Cells were plated on culture plates and cultured for
24 h to permit adherence. After attachment, each agent was added to
the culture medium. The control was treated with the vehicle alone.
2.3. PGI2 and PGE2 assay
PGI2 production was determined using culture medium from 48-h
cultured A549 cells (6 · 106 cells/100 mm dish). After 48 h culture,
the culture medium was collected, and the PGI2 level was subsequently
determined as the main metabolite of PGI2, 6-keto-PGF1a, using an
ELISA kit (Cayman Chemical Co.). The amount of PGE2 was mea-
sured according to a similar procedure.
2.4. RT-PCR
Total RNA was isolated from cultured A549 cells as described pre-
viously [17]. Transcripts were ampliﬁed by RT-PCR using primers
PPARd (NCBI reference number 60115372): sense primer (nucleotides
1–18), antisense primer (nucleotides 244–261); IP (NCBI 29825394):
sense primer (nucleotides 502–519), antisense primer (nucleotides
735–752); PPARa (NCBI 7549810): sense primer (nucleotides 174–
193), antisense primer (nucleotides 313–332); PPARc (NCBI
30583400): sense primer (nucleotides 63–82), antisense primer (nucleo-
tides 517–536); GAPDH (NCBI 7669491): sense primer (nucleotides
174–193), antisense primer (nucleotides 313–332). GAPDH was used
as an internal control. After 35 cycles, PCR products were separated
by electrophoresis (1.5% agarose gel) and stained with GelStar
(BMA, Rockland, ME, USA). A wide-range DNA ladder (Takara,
Shiga, Japan) was used as a marker to size the PCR products. When
negative results were observed, fresh polymerase was added after 35 cy-
cles, and the PCR was continued to 70 cycles to conﬁrm the negative
result. We also conﬁrmed the performance of PCR for PPARa, using
human kidney cDNA as a positive control (data not shown).
2.5. Assessment of cell viability
Cell viability was examined using a WST-1 assay kit (Quick Cell
Proliferation Assay Kit, MBL, Nagoya, Japan), according to the man-
ufacturers instructions.
2.6. SiRNA design, preparation and transfection
The design of short interfering RNA (siRNA) was carried out using
an on-line design system for siRNA (Qiagen, Germantown, MD). siR-
NAs were synthesized in high performance purity grade by Qiagen.
The sense and anti-sense strands of IP siRNA were: sense: 5 0-AAC-
GUCGUCCAAAGCAGAAGCdTdT-3 0; anti-sense: 5 0-GCUUCUG-
CUUUGGACGACGUUdTdT-3 0. The sense and anti-sense strands
of non-speciﬁc control siRNA were: sense: 5 0-UUCUCCGAACGU-
GUCACGUdTdT-3 0; anti-sense: 5 0-ACGUGACACGUUCGGA-
GAAdTdT-3 0. SiRNA was transfected into A549 cells using
RNAiFect Transfection Reagent (Invitrogen) as previously reported
[18]. At 12 h after transfection, the cells were incubated for 72 h in cul-
ture medium containing 20 lM cPGI2 or the vehicle, and the IP expres-
sion was subsequently determined by RT-PCR. Cell viability was
estimated by WST-1 assay.Fig. 1. The production of PGI2 and PGE2 (A), and expression pattern
of each PPAR subtype and IP in A549 cells. (A) A549 cells were
cultured for 48 h, and subsequently each PG level in culture media was
determined by ELISA as described in Section 2.3. The amount of PGI2
was measured as 6-keto-PGF1a. Each value indicates the mean of ﬁve
samples; vertical lines indicate S.D. (B) RT-PCR analyses were
performed as described in Section 2.4. The results shown are
representative of three independent experiments.2.7. Luciferase assay
A synthetic, triplicated PPAR-responsive element (PPRE)-ﬁreﬂy
luciferase reporter vector, containing three copies of PPRE for hydrox-
ymethylglutaryl-CoA reductase [19], was constructed as previously re-
ported [20]. The triplicated PPRE were subcloned into the MluI–XhoI
site of pGL3-promoter vector (Promega, Madison, WI, USA). A549
cells (5 · 104 cells/well in 12-well plates) were cotransfected with the
triplicated PPRE-ﬁreﬂy luciferase reporter vector and renilla luciferase
expression vector using Gene Jamar Transfect Reagent (Stratagene,
LaJolla, CA, USA). After 24 h of transfection, the cells were washed
with PBS, incubated with FBS-free DMEM containing 20 lM cPGI2
or L-165046 at the indicated doses for 24 h at 37 C. After incubation,
the cells were harvested and the ﬁreﬂy luciferase and renilla luciferaseactivities were quantiﬁed. The ﬁreﬂy luciferase activity of the extract
was normalized with the renilla luciferase activity. We also conﬁrmed
that the above treatment did not aﬀect the basic activity of the pGL3-
promoter vector alone (data not shown).
2.8. Immunoblot analysis
The cells were lysed in 1 ml of ice-cold lysis buﬀer (50 mM HEPES
(pH 7.5), 150 mM NaCL, 10% glycerol, 1 mM EDTA, 1% Triton X-
100, 10 mM b-glycerol phosphate, 0.1 mM sodium vanadate, 1 mM
NaF, 10 lg/ml leupeptin, 10 lg/ml aprotinin, 1 mM PMSF, 1 mM
DTT). The lysates were separated on 10 or 15% SDS–PAGE, trans-
ferred to a nitrocellulose membrane and subjected to immunoblotting
with anti-proliferating cell nuclear antigen (PCNA), anti-cyclin D
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p53, anti-
p21, anti-Bcl-xL and anti-b-actin (BD Sciences, Tokyo, Japan). Detec-
tion was accomplished using the ECL system (Amersham, Piscataway,
NJ) and a cooled CCD camera-linked Cool Saver system (Atto, To-
kyo, Japan). Molecular sizing was estimated using a Rainbow Molec-
ular Weight Marker (Amersham). Protein concentrations were
determined using a DC Protein Assay kit (Bio-rad, Tokyo, Japan).
2.9. Cell cycle analysis
Cells were suspended in PBS containing 70% ethanol, and kept at
4 C for 30 min. Before analysis, cells were incubated for 30 min in
propidium iodide (PI) solution containing 0.05 mg/ml PI, 1 mM
EDTA, 0.1% Triton X-100, and 1 mg/ml RNase A in PBS. The suspen-
sion was then passed through a nylon mesh ﬁlter and analyzed on a
Becton–Dickinson FACScan.
2.10. Apoptosis assay
To estimate apoptosis quantitatively, its induction was determined
by the ratio of subG1 population to the total cells in the cell cycle mea-
sured as above, and caspase 3 activity was measured using a Caspase-3/
CPP32 Assay Kit (Biovision, Mountain View, CA, USA) according to
the manufacturers instructions.
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5 · 106 cells were homogenized in perchloric acid and then centri-
fuged at 8000 · g for 5 min. Aliquots of the supernatant were then neu-
tralized and dansyl chloride was added. The dansyl derivatives were
then extracted with benzene and separated by high performance liquid
chromatography [21]. To determine the level of spermidine/spermineFig. 2. The eﬀects of cPGI2 on the viability of A549 cells in a dose-dependen
RpcAMP (C). (A) The cells were treated with cPGI2 at indicated doses for 7
value indicates the mean of eight samples; vertical lines indicate S.D. (B) Trea
was conﬁrmed by RT-PCR analysis as described in Section 2.4. NSSiRNA, no
cPGI2, cPGI2 treatment; cPGI2 + NSSiRNA, co-treatment of cPGI2 and NS
value indicates the mean of ﬁve samples; vertical lines indicate S.D. \Signiﬁc
20 lM cPGI2 and/or 40 lM RpcAMP for 72 h, and then cell viability was de
eight samples; vertical lines indicate S.D. \Signiﬁcant diﬀerence from three oN1-acetyltransferase (SSAT) mRNA, real-time RT-PCR was carried
out. cDNA synthesis for SSAT and GAPDH was described above.
PCR reactions were carried out using SSAT primers (NCBI reference
number 33876789): sense primer (nucleotides 356–375); antisense pri-
mer (nucleotides 543–562); GAPDH as above and SYBR green dye.
Reactions were performed at 94 C for 1 min, followed by 40 cyclest manner (A), under IP silencing by SiRNA (B), and in the presence of
2 h, and cell viability was determined as described in Section 2.5. Each
tment conditions were described in Section 2.6. IP silencing by SiRNA
n-speciﬁc control SiRNA treatment; SiRNA, SiRNA for IP treatment;
SiRNA; cPGI2 + NSSiRNA, co-treatment of cPGI2 and SiRNA. Each
ant diﬀerence from three other groups. (C) The cells were treated with
termined as described in Section 2.5. Each value indicates the mean of
ther groups.
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detected with the ABI Prism 7700 Sequence Detector (Perkin Elmer
Biosystems). The abundance of ampliﬁed DNA was determined from
the threshold cycle values and normalized to the values for control
gene GAPDH to yield the relative abundance. The values of SSAT/
GAPDH were normalized to those of the control.
2.12. Statistical analysis
Data were analyzed by one-way analysis of variance followed by
Dunnetts multiple-range test. A P value of 0.05 or less was considered
signiﬁcant.3. Results and discussion
We ﬁrst determined the production levels of PGI2 (6-keto-
PGF1a) and PGE2 of the A549 cell line to examine its ade-
quacy in exhibiting the same pattern of PG synthesis as that
of human lung adenocarcinoma tissues. As shown in Fig.
1A, the production of 6-keto-PGF1a was much lower than that
of PGE2, thus it appears that the PG synthesis pattern of A549
cells is the same as that of human lung adenocarcinoma tissue.
Next, we checked the expression patterns of IP and PPAR spe-
cies in A549 cells. We observed the expression of PPARd,Fig. 3. The eﬀects of L-165041 on cell viability (A), transactivity of PPARd (B
progression (D) in A549 cells. (A) The cells were treated with L-165041 at the
in Section 2.5. Each value indicates the mean of eight samples; vertical line
(10 lM)-treated group. (B) Treatment and luciferase assay were performed as
vertical lines indicate S.D. \Signiﬁcant diﬀerence from the control and L-165
the indicated doses for 48 h, and each protein level was determined by im
representative of three independent experiments. (D) The cells were treated w
performed as described in Section 2.9. Each value represents the mean of thPPARc and IP but not PPARa in the cells, indicating that
PGI2 signaling depended on both IP- and PPARd-regulated
signal pathways. In addition, the expression pattern of PPARc
and PPARa in A549 cells was identical to that of other human
lung adenocarcinoma cells [22]. Taken together, the expression
pattern of IP and PPAR species in A549 cells may be generally
observed in human lung adenocarcinoma cells, and A549 cells
are suitable to estimate the role of PGI2 signaling in human
lung adenocarcinoma cells.
As mentioned above, PGI2 functions through a G protein-
coupled cell surface receptor, IP and a nuclear hormone recep-
tor, PPARd. We ﬁrst examined whether signaling via these two
receptors could produce the negative growth control of A549
cells, using an agonist for IP and PPARd, cPGI2. Although
cPGI2 also acts as an agonist for PPARa, the agonist only in-
duces PPARd activation in A549 cells because the cells do not
express PPARa. Although we conﬁrmed that cPGI2 induced
the activation of PPARd under this treatment condition (data
not shown), the agonist did not aﬀect the cell growth of A549
cells at the treatment dose, 20 lM (Fig. 2A). A recent report
demonstrated that downstream signaling regulated by IP has
an antagonistic eﬀect against PPARd-dependent negative
growth signaling in some cells [20]. Based on this report, we), the levels of molecules related to cell proliferation (C), and cell cycle
indicated doses for 72 h, and cell viability was determined as described
s indicate S.D. \Signiﬁcant diﬀerence from the control and L-165041
described in Section 2.7. Each value indicates the mean of ﬁve samples;
041 (10 lM)-treated group. (C) The cells were treated with L-165041 at
munoblot analysis as described in Section 2.8. The results shown are
ith L-165041 at the indicated doses for 48 h, and cell cycle analysis was
ree experiments.
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PPARd-dependent signaling might be related to the result
shown in Fig. 2A. To determine this possibility, we next exam-
ined whether cPGI2 could induce negative growth control in
A549 cells by the suppression of IP expression. As shown in
Fig. 2B, cPGI2 reduced the cell growth of A549 cells under
IP silencing by SiRNA treatment. We also conﬁrmed that
SiRNA alone did not aﬀect cell growth (Fig. 2B). These
results suggest that IP-regulated signaling interferes with
PPARd-dependent signaling related to cell growth control.
IP activation by agonists leads to the increased production
of intracellular cAMP via the stimulation of adenylate cyclase
[10], therefore we next explored whether cAMP could act as a
second messenger contributing to the antagonistic eﬀect of IP.
As shown in Fig. 2C, a speciﬁc cAMP antagonist, the Rp iso-
mer of adenosine 3 0,5 0-cyclic monophosphate (RpcAMP), in-
duced negative growth control in A549 cells treated with
cPGI2, suggesting that the IP-cAMP pathway serves to protect
A549 cells from PPARd-dependent negative growth control.
To further conﬁrm the contribution of PPARd-dependent sig-
naling in the negative growth control of A549 cells, we examinedFig. 4. The eﬀects of indomethacin on cell viability (A), subG1 population (B
(D) in A549 cells treated with L-165041. IDMC, indomethacin treatmen
indomethacin for 72 h, and then cell viability was determined as described in S
indicate S.D. \Signiﬁcant diﬀerence from the control and indomethacin-treat
cells were treated with 20 lM L-165041 and/or 20 lM indomethacin for 72 h,
in Section 2.9. SubG1 population was calculated from the ratio of the cell nu
and G2/M phases). Each value indicates the mean of three samples; vertical
Cell treatment was carried out as described in Fig. 4B. Caspase3 activity was
of eight samples; vertical lines indicate S.D. \Signiﬁcant diﬀerence from three
20 lM indomethacin for 48 h, and each protein level was determined by im
representative of three independent experiments.the eﬀect of a PPARd agonist, L-165041, on the growth of A549
cells. As shown in Fig. 3A, L-165041 retarded the growth of
A549 cells with statistical signiﬁcance when treated with either
20 or 40 lM. In addition, the agonist induced PPARd activation
(Fig. 3B). In a recent report, it was shown that L-165041 can act
as a PPARc ligand in addition to PPARd [23]. However, we pre-
viously observed that at doses less than 40 lM,L-165041 did not
induce PPARc activation in cells with only PPARc expression
(data not shown), so we can rule out the possibility that
L-165041 stimulated PPARc under this treatment condition.
Taken together, it seems that PPARd is required for the
L-165041-driven negative growth control of A549 cells. Next,
we tried to clarify the possible mechanism of PPARd-regulated
cell growth control. As shown inFig. 3C,L-165041 treatment re-
duced both the level of cyclin D responsible for G1 to S phase
transition and the level of PCNA, a cell proliferation marker,
and linked with this event, the treatment induced G1 arrest in
A549 cells (Fig. 3D). However, the treatment did not cause
apoptosis in A549 cells (data not shown). These results suggest
that PPARd-dependent growth control depends on a cytostatic
eﬀect based on G1 arrest but not a cytotoxic eﬀect.), caspase3 activity (C), and the levels of molecules related to apoptosis
t. (A) The cells were treated with 20 lM L-165041 and/or 20 lM
ection 2.5. Each value indicates the mean of eight samples; vertical lines
ed group and \\signiﬁcant diﬀerence from other three groups. (B) The
and then the subG1 population was determined by FACS as described
mber in the subG1 phase to the total cell number of cell cycles (G1, S,
lines indicate S.D. \Signiﬁcant diﬀerence from other three groups. (C)
determined as described in Section 2.10. Each value indicates the mean
other groups. (D) The cells were treated with 20 lM L-165041 and/or
munoblot analysis as described in Section 2.8. The results shown are
Fig. 5. The combination eﬀect of L-165041 and indomethacin on the
levels of total polyamine (A) and SSAT mRNA (B) in A549 cells. (A)
The cells were treated with 20 lM L-165041 and/or 20 lM indometh-
acin for 72 h, and each polyamine (putrescine, spermidine, and
spermine) was determined by HPLC as described in Section 2.11.
Total polyamine level was expressed as the sum of each polyamine
level. Total polyamine level in the control was 21.5 pmol/mg protein.
Each value indicates the mean of ﬁve samples; vertical lines indicate
S.D. \Signiﬁcant diﬀerence from the control and \\signiﬁcant diﬀerence
from three other groups. IDMC, indomethacin treatment. (B) The cells
were treated with 20 lM L-165041 and/or 20 lM indomethacin for
48 h, and SSAT mRNA level was determined by real-time PCR and
quantiﬁed as the ratio of SSAT/GAPDH. Each value indicates the
mean of three samples; vertical lines indicate S.D. \Signiﬁcant
diﬀerence from the control and indomethacin-treated group and
\\signiﬁcant diﬀerence from three other groups.
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quent overproduction of PGs except PGI2 contribute to the
appearance of malignant phenotypes in lung adenocarcinoma
cells [6,14]. From these reports, it can be assumed that the
overproduction of PGs by COX except PGI2 attenuates the
PPARd-dependent negative growth control of A549 cells, so
we examined the eﬀect of L-165041 treatment on the growth
of A549 cells under COX inhibition by indomethacin. We also
conﬁrmed that COX inhibition in A549 cells reached a plateau
(data not shown) under the same indomethacin treatment
conditions stated in the Fig. 4 legend. As shown in Fig. 4A,
indomethacin treatment signiﬁcantly reinforced the L-165041-
driven negative growth control of A549 cells. Furthermore,
we conﬁrmed that reinforcement by indomethacin depended
on the induction of apoptosis (Fig. 4B and C). Moreover, we
observed that the combination of L-165041 and indomethacin
reduced the level of Bcl-xL, an anti-apoptotic molecule and in-
duced Bax, a pro-apoptotic molecule related to the upregula-
tion of p53 (Fig. 4D), indicating that indomethacin caused
apoptosis in A549 cells treated with L-165041 by elevating
the ratio of Bax to Bcl-xL. Overall, it seems that signaling reg-
ulated by PGs except PGI2 prevents A549 cells from being
inﬂuenced by PPARd-dependent negative growth control. Fi-
nally, we tried to determine which factors could relate to the
induction of apoptosis in A549 cells co-treated with L-
1650041 and indomethacin. In previous reports, indomethacin
has been shown to exert a chemopreventive action by aﬀecting
polyamine metabolism in colon cancers, and reduced intracel-
lular polyamine contents led to the induction of apoptosis
[24,25]. We have also reported that indomethacin suppresses
the elevation of polyamine at the promotion stage of lung
tumorigenesis in mice [26,27]. Furthermore, it has been re-
ported that the activation of PPARd can induce the transcrip-
tional activation of SSAT, a key polyamine catabolic enzyme
[28]. Based on these results, we hypothesized that the reduction
of polyamine levels via the induction of SSAT by co-treatment
could act as an apoptotic mediator. As shown in Fig. 5A, the
co-treatment of L-165041 and indomethacin reduced the total
polyamine level with statistical signiﬁcance compared to the
control, L-165041-treated and indomethacin-treated groups,
while either L-165041 treatment or indomethacin treatment
alone also reduced the polyamine level, but the reduction in le-
vel was much less than that exhibited by the co-treated group.
In contrast, the diﬀerence of SSAT mRNA level in each treat-
ment group showed an opposite tendency with the change in
polyamine level (Fig. 5B). These results suggest that the severe
reduction of the polyamine level via the induction of SSAT by
co-treatment is an important factor to induce apoptosis. This
speculation can be supported by the result that the co-treat-
ment-induced cytotoxicity of A549 cells was abrogated by
exogenous putrescine (a polyamine) (data not shown).
As mentioned, the exact roles of suppression of PGI2 syn-
thesis in lung adenocarcinoma cells are unclear. In this study,
we observed that, irrespective of the low level of PGI2, both
PGI2 receptors (PPARd and IP) were expressed in A549 cells.
Thus, if PGI2 level elevation should occur in the cells,
PPARd and/or IP-dependent signaling would be activated
and this activation might inﬂuence the growth of cancer cells.
We conﬁrmed that the activation of PPARd but not IP-in-
duced the negative growth control of A549 cells. Since
PGI2 is extremely unstable, endogenously produced PGI2 in
the cells can interact with intracellular PPARd but not easilyinteract with IP located on the cell surface [20]. Thus, theo-
retically, it can be assumed that IP-dependent signaling has
an antagonistic eﬀect on the PPARd-induced negative growth
of cancer cells, but, due to the instability of PGI2, the in vivo
antagonistic eﬀect may be very weak or actually negative. Ta-
ken together, it seems that the suppression of PGI2 synthesis
in lung adenocarcinoma cells serves to protect cancer cells
from intracellular PGI2-PPARd-mediated negative growth
control. As far as we know, this result is the ﬁrst report to
show why the level of PGI2 is much lower than that of other
PGs in lung adenocarcinoma cells.
In this study, we observed that the inhibition of COX rein-
forced the PPARd-dependent negative growth control of
A549 cells and induced cell apoptosis. This observation can
be supported by results that the treatment reduced the level
of Bcl-xL and upregulated Bax via the induction of p53. In
our previous study, we reported that PGE2 induces Bcl-xL
due to the activation of Src-signal transducers and activators
of transcription 3 [29], but this result indicated that the sup-
pression of PGE2 production by indomethacin treatment alone
was insuﬃcient to reduce the level of Bcl-xL. Similarly,
K. Fukumoto et al. / FEBS Letters 579 (2005) 3829–3836 3835although a previous report suggested that the inhibition of
COX by indomethacin is suﬃcient to induce p53-Bax signaling
in cancer cells [30], the inhibition of COX alone in this study
could not cause signal induction. However, the combination
of indomethacin treatment and PPARd activation induced
apoptosis in A549 cells due to the reduction of Bcl-xL and
upregulation of p53-Bax signaling. These results indicate that
common factors regulated by the inhibition of PG synthesis
and PPARd activation are required for the induction of apop-
tosis in A549 cells. It has been reported that the activation of
PPARd stimulates polyamine catabolism via the induction of
SSAT, leading to a decreased polyamine level in cancer cells
[31] and that indomethacin treatment reduced the polyamine
level in tumor tissues [28]. In addition to these reports, the cel-
lular polyamine level is considered a key determinant to induce
a cytostatic or cytotoxic eﬀect in cells [32,33]. Overall, it is
likely that the cellular polyamine level in A549 cells acts as a
determinant to induce cytostatic or cytotoxic eﬀects as ob-
served in this study. Our evidence shows that, in A549 cells,
a moderate reduction of the polyamine level by L-165401 led
to the induction of a cytostatic eﬀect but not a cytotoxic eﬀect,
whereas severe reduction of the level by the L-165401/indo-
methacin combination caused a cytotoxic eﬀect. From these re-
ports and our results, it is concluded that the activation of
PPARd under the suppression of PG synthesis is a promising
strategy to regulate lung cancer cell growth.
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